ATE307595T1 - Verwendung von synthetischen fxr liganden zur behandlung von krankheiten die mit einem gestörten gleichgewicht des cholesterin-spiegels verbunden sind und von kolonkrebs - Google Patents
Verwendung von synthetischen fxr liganden zur behandlung von krankheiten die mit einem gestörten gleichgewicht des cholesterin-spiegels verbunden sind und von kolonkrebsInfo
- Publication number
- ATE307595T1 ATE307595T1 AT00941312T AT00941312T ATE307595T1 AT E307595 T1 ATE307595 T1 AT E307595T1 AT 00941312 T AT00941312 T AT 00941312T AT 00941312 T AT00941312 T AT 00941312T AT E307595 T1 ATE307595 T1 AT E307595T1
- Authority
- AT
- Austria
- Prior art keywords
- imbalance
- treatment
- colon cancer
- diseases associated
- cholesterol levels
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 206010009944 Colon cancer Diseases 0.000 title 1
- 208000029742 colonic neoplasm Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000260 hypercholesteremic effect Effects 0.000 abstract 1
- 230000000871 hypocholesterolemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13896899P | 1999-06-11 | 1999-06-11 | |
| PCT/US2000/015912 WO2000076523A1 (en) | 1999-06-11 | 2000-06-09 | Methods for modulating fxr receptor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE307595T1 true ATE307595T1 (de) | 2005-11-15 |
Family
ID=22484498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00941312T ATE307595T1 (de) | 1999-06-11 | 2000-06-09 | Verwendung von synthetischen fxr liganden zur behandlung von krankheiten die mit einem gestörten gleichgewicht des cholesterin-spiegels verbunden sind und von kolonkrebs |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1185277B1 (de) |
| JP (1) | JP2003501477A (de) |
| CN (1) | CN1368884A (de) |
| AT (1) | ATE307595T1 (de) |
| AU (1) | AU768806B2 (de) |
| BR (1) | BR0011743A (de) |
| CA (1) | CA2377320A1 (de) |
| DE (1) | DE60023493T2 (de) |
| HK (1) | HK1047705A1 (de) |
| WO (1) | WO2000076523A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020132223A1 (en) * | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
| US20020119958A1 (en) * | 2001-02-13 | 2002-08-29 | Shinichiro Tojo | Therapeutic agent for hyperlipidemia |
| AU2002308295B2 (en) | 2001-03-12 | 2007-08-23 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
| US20030144360A1 (en) * | 2001-11-19 | 2003-07-31 | Allergan Sales, Inc. | Composition and method for modulating BAR/FXR receptor activity |
| ES2367539T3 (es) | 2001-12-21 | 2011-11-04 | X-Ceptor Therapeutics, Inc. | Moduladores heterocíclicos de receptores nucleares. |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| US20050143449A1 (en) * | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
| EP1734970B1 (de) | 2004-03-12 | 2014-12-31 | Intercept Pharmaceuticals, Inc. | Behandlung von fibrose mit fxr-liganden |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| AU2008209566C1 (en) | 2007-01-19 | 2013-02-14 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as TGR5 modulators and methods of use thereof |
| EA020310B1 (ru) | 2008-07-30 | 2014-10-30 | Интерсепт Фармасьютикалз, Инк. | Модуляторы рецептора tgr5 и их применение |
| ES2663948T3 (es) | 2008-11-19 | 2018-04-17 | Intercept Pharmaceuticals, Inc. | Moduladores de TGR5 y método de uso de los mismos |
| US20110257139A1 (en) | 2008-12-19 | 2011-10-20 | Royal College Of Surgeons In Ireland | Treatment of diarrhoea |
| US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
| NZ734451A (en) | 2012-06-19 | 2018-12-21 | Intercept Pharmaceuticals Inc | Preparation, uses and solid forms of obeticholic acid |
| SI3043865T1 (sl) | 2013-09-11 | 2021-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B |
| WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| EP3999101A1 (de) | 2019-07-18 | 2022-05-25 | ENYO Pharma | Verfahren zur verringerung von störeffekten von interferon |
| WO2021144330A1 (en) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| KR20230154806A (ko) | 2021-01-14 | 2023-11-09 | 엔요 파마 | Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과 |
| CN117320722A (zh) | 2021-04-28 | 2023-12-29 | 埃尼奥制药公司 | 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588715A (en) * | 1984-06-04 | 1986-05-13 | Sandoz, Inc. | Heptenoic acid derivatives |
| FR2707989B1 (fr) * | 1993-07-22 | 1995-10-13 | Pf Medicament | Nouveaux dérivés de benzylamines silylées, leurs sels, leurs procédés de fabrication et les compositions pharmaceutiques les renfermant. |
-
2000
- 2000-06-09 BR BR0011743-9A patent/BR0011743A/pt not_active IP Right Cessation
- 2000-06-09 CA CA002377320A patent/CA2377320A1/en not_active Abandoned
- 2000-06-09 DE DE60023493T patent/DE60023493T2/de not_active Expired - Fee Related
- 2000-06-09 CN CN00811519A patent/CN1368884A/zh active Pending
- 2000-06-09 JP JP2001502856A patent/JP2003501477A/ja active Pending
- 2000-06-09 EP EP00941312A patent/EP1185277B1/de not_active Expired - Lifetime
- 2000-06-09 WO PCT/US2000/015912 patent/WO2000076523A1/en not_active Ceased
- 2000-06-09 AT AT00941312T patent/ATE307595T1/de not_active IP Right Cessation
- 2000-06-09 AU AU56032/00A patent/AU768806B2/en not_active Ceased
- 2000-06-09 HK HK02109359.4A patent/HK1047705A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003501477A (ja) | 2003-01-14 |
| DE60023493D1 (de) | 2005-12-01 |
| CA2377320A1 (en) | 2000-12-21 |
| AU768806B2 (en) | 2004-01-08 |
| EP1185277A1 (de) | 2002-03-13 |
| CN1368884A (zh) | 2002-09-11 |
| EP1185277B1 (de) | 2005-10-26 |
| DE60023493T2 (de) | 2006-07-20 |
| HK1047705A1 (zh) | 2003-03-07 |
| WO2000076523A1 (en) | 2000-12-21 |
| BR0011743A (pt) | 2002-03-05 |
| AU5603200A (en) | 2001-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE307595T1 (de) | Verwendung von synthetischen fxr liganden zur behandlung von krankheiten die mit einem gestörten gleichgewicht des cholesterin-spiegels verbunden sind und von kolonkrebs | |
| DE69722681D1 (de) | Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen | |
| DE60033030D1 (de) | Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit | |
| ATE330630T1 (de) | Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| ATE200863T1 (de) | Indolinonverbindungen zur behandlung von krankheiten | |
| DE60032226D1 (de) | Verfahren zur induktion von krebszellentod und tumorregression | |
| DE69838338D1 (de) | Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen | |
| ATE297036T1 (de) | Verfahren und vorrichtung zum vorhersagen von menschlichen kognitiven leistung | |
| ATE337021T1 (de) | Anordnungen, systeme und verfahren zur behandlung von biologischen flüssigkeiten mit licht | |
| DE69839815D1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
| DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| DE69941154D1 (de) | Verwendung von Hydroxamatverbindungen zur Behandlung von HER-2/neu positiven Karzinomen | |
| DE69715000D1 (de) | Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens | |
| ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
| DE69524623D1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
| DE69331605D1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| ATE384528T1 (de) | Verwendung von einem faktor a inhibierenden oligosacchariden mit einem blutgerinnungshemmenden mittel zur behandlung von arterienthrombosen | |
| DE69927876T2 (de) | Metallocenverbindung, und Verfahren zur Herstellung von Polyolefine unter Verwendung dieser | |
| DE69825286D1 (de) | Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen | |
| DE69840752D1 (de) | Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen | |
| ATE254128T1 (de) | Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen | |
| ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| WO2003043581A3 (en) | Composition and method for modulating bar/fxr receptor activity | |
| ATA901396A (de) | Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |